Eli Lilly and Company (NYSE:LLY) Stock Price Up 1% – Should You Buy?

Shares of Eli Lilly and Company (NYSE:LLY) rose 1% on Friday . The company traded as high as $1,271.22 and last traded at $1,257.26. Approximately 2,494,212 shares traded hands during trading, a decline of 20% from the average daily volume of 3,101,136 shares. The stock had previously closed at $1,244.40.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based biotech company Chai Discovery to develop an RNA vaccine platform. The partnership could expand Lilly’s long-term technology and vaccine pipeline, although financial details and near-term revenue implications were not disclosed. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Analyst enthusiasm remains strong, with Lilly identified as a leading candidate among stocks expected to deliver substantial earnings growth. This supports the bullish investment narrative surrounding its obesity and diabetes medicines. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Positive Sentiment: Reports that Lilly’s obesity treatments are outpacing Novo Nordisk strengthen expectations for continued market-share gains. Investors are also watching the developing race in oral GLP-1 treatments, which could create another major growth opportunity beyond injectable medicines. Eli Lilly’s obesity treatments outpace Novo Nordisk
• Positive Sentiment: Lilly completed a Phase 2b study of a treatment for hidradenitis suppurativa, adding depth to its immunology pipeline. The update is potentially supportive for the stock, though investors will need efficacy and regulatory data before assigning meaningful value. Eli Lilly Completes Mid-Stage Hidradenitis Suppurativa Trial, Adding Depth to Its Immunology Pipeline
• Neutral Sentiment: Several early- and late-stage study updates involving LY4178256, eloralintide, mirikizumab, lebrikizumab, dulaglutide, and other immunology programs indicate ongoing pipeline progress, but the announcements did not provide results likely to materially change near-term earnings expectations.
• Neutral Sentiment: Speculation that Lilly could announce a stock split reflects its high per-share price and strong appreciation. A split would improve trading accessibility but would not change the company’s intrinsic value or market capitalization. Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Berenberg Bank raised their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, Rothschild & Co Redburn boosted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The business has a 50-day moving average price of $1,177.74 and a 200 day moving average price of $1,058.43. The stock has a market capitalization of $1.18 trillion, a P/E ratio of 42.19, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last three months. 0.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. lifted its stake in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $356,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.